These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 16618404

  • 1. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T, Nonresponder Retreatment Group.
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C, Hollinger FB, Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F, Moore DH, Gish RG.
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
    Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.
    J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.
    BMC Infect Dis; 2010 Jul 20; 10():212. PubMed ID: 20646277
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
    Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D.
    Liver Int; 2007 Sep 20; 27(7):954-9. PubMed ID: 17696934
    [Abstract] [Full Text] [Related]

  • 10. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
    Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, El Ray A, Cazals-Hatem D, Vidaud D, Valla D, Bourlière M, Marcellin P.
    J Hepatol; 2007 Apr 20; 46(4):596-604. PubMed ID: 17218037
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A, Arase Y, Suzuki F, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.
    J Gastroenterol; 2004 Apr 20; 39(2):155-61. PubMed ID: 15069622
    [Abstract] [Full Text] [Related]

  • 17. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
    Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A.
    Ann Intern Med; 2009 Apr 21; 150(8):528-40. PubMed ID: 19380853
    [Abstract] [Full Text] [Related]

  • 18. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E.
    World J Gastroenterol; 2014 Nov 28; 20(44):16726-33. PubMed ID: 25469044
    [Abstract] [Full Text] [Related]

  • 19. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.
    Liver Int; 2011 Mar 28; 31(3):401-11. PubMed ID: 21281434
    [Abstract] [Full Text] [Related]

  • 20. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.
    Clin Infect Dis; 2009 Apr 15; 48(8):1152-9. PubMed ID: 19275492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.